AVI BioPharma, Inc. Reports Successful Inhibition Of Multiple Subtypes Of Influenza A Using NEUGENE Antisense Therapeutic

PORTLAND, Ore.--(BUSINESS WIRE)--March 30, 2006--Preclinical Results by Four Independent Laboratories Summarized and Presented at Keystone Symposia: Advances in Influenza Research. AVI BioPharma, Inc. (Nasdaq:AVII), today announced the presentation of research results titled “Inhibition of Multiple Subtypes of Influenza A Virus in Cell Culture with Morpholino Oligomers” at the Keystone Symposia conference “Advances in Influenza Research: From Birds to Bench to Bedside.” The symposium will be held March 28 to April 2, 2006, in Steamboat Springs, Colo.